Mallinckrodt plc Announces Poster Presentation on TERLIVAZ® at Kidney Week 2024

Introduction

Mallinckrodt plc, a global specialty pharmaceutical company, presented a pooled analysis from Phase 3 clinical trials highlighting liver transplant rates in adult patients with Hepatorenal Syndrome (HRS) with rapid reduction in kidney function treated with TERLIVAZ. The presentation took place at Kidney Week 2024, the annual meeting of the American Society of Nephrology, and showcased the efficacy of TERLIVAZ in improving kidney function in patients with this acute and life-threatening condition.

Key Findings

The data presented at Kidney Week 2024 underscored the importance of TERLIVAZ in the treatment of HRS with rapid reduction in kidney function. This condition, which affects more than 42,000 Americans annually, is considered very rare but rates of hospitalizations are on the rise. TERLIVAZ is the first and only FDA-approved product indicated for improving kidney function in adults with this condition, making it a significant breakthrough in the field of nephrology.

Limitation of Use and Important Safety Information

It is crucial to consider the Limitation of Use and Important Safety Information when prescribing TERLIVAZ. Healthcare providers should be aware of the Boxed Warning associated with this medication and take necessary precautions to ensure patient safety.

Impact on Individuals

For individuals suffering from HRS with rapid reduction in kidney function, the availability of TERLIVAZ could mean a significant improvement in their quality of life. By addressing the underlying kidney dysfunction, this medication has the potential to reduce the need for liver transplants and decrease the risk of serious complications associated with HRS.

Impact on the World

The introduction of TERLIVAZ as a treatment option for HRS with rapid reduction in kidney function could have a profound impact on the medical community worldwide. This breakthrough medication has the potential to change the standard of care for patients with this rare condition and improve outcomes on a global scale.

Conclusion

In conclusion, the poster presentation on TERLIVAZ at Kidney Week 2024 highlights the advancements in the treatment of Hepatorenal Syndrome with rapid reduction in kidney function. This groundbreaking medication offers new hope for patients facing this life-threatening condition and paves the way for future innovations in nephrology.